Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2012 by Bayside Health.
Recruitment status was  Active, not recruiting
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Bayside Health Identifier:
First received: June 1, 2011
Last updated: December 3, 2012
Last verified: December 2012